• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

轴向手性N-苄基-N,7-二甲基-5-苯基-1,7-萘啶-6-甲酰胺衍生物作为速激肽NK1受体拮抗剂:绝对立体化学要求的测定

Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1, 7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of the absolute stereochemical requirements.

作者信息

Ikeura Y, Ishichi Y, Tanaka T, Fujishima A, Murabayashi M, Kawada M, Ishimaru T, Kamo I, Doi T, Natsugari H

机构信息

Pharmaceutical Research Division and Technology Development Department, Takeda Chemical Industries, Ltd., 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532, Japan.

出版信息

J Med Chem. 1998 Oct 22;41(22):4232-9. doi: 10.1021/jm980042m.

DOI:10.1021/jm980042m
PMID:9784098
Abstract

A potent and orally active NK1 antagonist, trans-N-[3, 5-bis(trifluoromethyl)benzyl]-7,8-dihydro-N, 7-dimethyl-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide (1t), was shown to exist as a mixture of separable and stable (R)- and (S)-atropisomers (1t-A and 1t-B) originating from the restricted rotation around the -C(6)-C(=O)- bond; the antagonistic activities of 1t-A were ca. 6-13-fold higher than those of 1t-B. Analogues of 1t (3), which have (S)- and (R)-methyl groups at the benzylic methylene portion of 1t, were prepared and separated into the diastereomeric atropisomers, 3a-A, 3a-B and 3b-A, 3b-B, in enantiomerically pure forms. Among the four isomers of 3, the (aR, S)-enantiomer (3a-A) exhibited the most potent antagonistic activities with an IC50 value of 0.80 nM (in vitro inhibition of [125I]BH-SP binding in human IM-9 cells) and ED50 values of 9.3 micrograms/kg (iv) and 67.7 micrograms/kg (po) (in vivo inhibition of capsaicin-induced plasma extravasation in guinea pig trachea), while the activity of the (aS,R)-enantiomer (3b-B) was the weakest with an IC50 value of 620 nM. The structure-activity relationships in this series of antagonists indicate that the (R)-configuration at the axial bond and the stacking (or stacking-like) conformation between the two phenyl rings as shown in 1t-A and 3a-A are essential for high-affinity binding and suggest that the amide moiety functions as a hydrogen bond acceptor in the interaction with the receptor.

摘要

一种强效且口服活性的NK1拮抗剂,反式-N-[3,5-双(三氟甲基)苄基]-7,8-二氢-N,7-二甲基-5-(4-甲基苯基)-8-氧代-1,7-萘啶-6-甲酰胺(1t),被证明是以可分离且稳定的(R)-和(S)-阻转异构体(1t-A和1t-B)的混合物形式存在,这是由于围绕-C(6)-C(=O)-键的旋转受限所致;1t-A的拮抗活性比1t-B高约6至13倍。制备了1t(3)的类似物,其在1t的苄基亚甲基部分具有(S)-和(R)-甲基,并分离成非对映体阻转异构体,即对映体纯形式的3a-A、3a-B和3b-A、3b-B。在3的四种异构体中,(aR,S)-对映体(3a-A)表现出最强的拮抗活性,IC50值为0.80 nM(在人IM-9细胞中对[125I]BH-SP结合的体外抑制),ED50值为9.3微克/千克(静脉注射)和67.7微克/千克(口服)(在豚鼠气管中对辣椒素诱导的血浆外渗的体内抑制),而(aS,R)-对映体(3b-B)的活性最弱,IC50值为620 nM。这一系列拮抗剂的构效关系表明,如1t-A和3a-A所示,轴向键处的(R)-构型以及两个苯环之间的堆积(或类似堆积)构象对于高亲和力结合至关重要,并表明酰胺部分在与受体的相互作用中作为氢键受体起作用。

相似文献

1
Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1, 7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of the absolute stereochemical requirements.轴向手性N-苄基-N,7-二甲基-5-苯基-1,7-萘啶-6-甲酰胺衍生物作为速激肽NK1受体拮抗剂:绝对立体化学要求的测定
J Med Chem. 1998 Oct 22;41(22):4232-9. doi: 10.1021/jm980042m.
2
Axially chiral 1,7-naphthyridine-6-carboxamide derivatives as orally active tachykinin NK(1) receptor antagonists: synthesis, antagonistic activity, and effects on bladder functions.轴向手性1,7-萘啶-6-甲酰胺衍生物作为口服活性速激肽NK(1)受体拮抗剂:合成、拮抗活性及对膀胱功能的影响
J Med Chem. 1999 Sep 23;42(19):3982-93. doi: 10.1021/jm990220r.
3
Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.结构优化得到2-(R)-(1-(R)-3,5-双(三氟甲基)苯乙氧基)-3-(S)-(4-氟)苯基-4-(3-氧代-1,2,4-三唑-5-基)甲基吗啉,一种强效、口服活性、长效的吗啉缩醛类人NK-1受体拮抗剂。
J Med Chem. 1998 Nov 5;41(23):4607-14. doi: 10.1021/jm980299k.
4
SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-双(三氟甲基)苯基]乙酰基]-2-(3,4-二氯苯基)-2-吗啉基]乙基]-4-哌啶基)-2-甲基丙酰胺],速激肽神经激肽-1受体的中枢活性非肽拮抗剂:I.生化和药理学特性
J Pharmacol Exp Ther. 2002 Dec;303(3):1171-9. doi: 10.1124/jpet.102.040162.
5
2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N - methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models.2-硝基苯基甲酰基-(S)-脯氨酰-(S)-3-(2-萘基)丙氨酰-N-苄基-N-甲基酰胺(SDZ NKT 343),一种强效的人NK1速激肽受体拮抗剂,在慢性疼痛模型中具有良好的口服镇痛活性。
J Med Chem. 1998 Aug 13;41(17):3159-73. doi: 10.1021/jm970499g.
6
Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK(1)/NK(2) receptor antagonist.N-[(R,R)-(E)-1-(3,4-二氯苄基)-3-(2-氧代氮杂环庚烷-3-基)氨基甲酰基]烯丙基-N-甲基-3,5-双(三氟甲基)苯甲酰胺的立体选择性制备,一种强效且口服活性的双重神经激肽NK(1)/NK(2)受体拮抗剂。
J Med Chem. 2003 Jul 31;46(16):3508-13. doi: 10.1021/jm030786m.
7
Potent NK1 receptor antagonists: synthesis and antagonistic activity of various heterocycles with an N-[3,5-bis(trifluoromethyl)benzyl]-N-methylcarbamoyl substituent.强效NK1受体拮抗剂:具有N-[3,5-双(三氟甲基)苄基]-N-甲基氨基甲酰取代基的各种杂环化合物的合成与拮抗活性
Chem Pharm Bull (Tokyo). 1997 Oct;45(10):1642-52. doi: 10.1248/cpb.45.1642.
8
Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist.(2R-反式)-4-[1-[3,5-双(三氟甲基)苯甲酰基]-2-(苯甲基)-4-哌啶基]-N-(2,6-二甲基苯基)-1-乙酰胺 (S)-羟基丁二酸酯(R116301)的药理学特性,一种口服且具有中枢活性的神经激肽-1受体拮抗剂。
J Pharmacol Exp Ther. 2002 Aug;302(2):696-709. doi: 10.1124/jpet.102.034348.
9
Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.ZD6021的药理学特性:一种新型的、口服活性速激肽受体拮抗剂。
J Pharmacol Exp Ther. 2001 Jul;298(1):307-15.
10
Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.新型三重神经激肽受体拮抗剂CS-003强烈抑制神经激肽相关反应。
Eur J Pharmacol. 2008 May 31;586(1-3):306-12. doi: 10.1016/j.ejphar.2008.02.056. Epub 2008 Mar 4.

引用本文的文献

1
Recent Progress in Cyclic Aryliodonium Chemistry: Syntheses and Applications.环状芳基碘鎓化学的最新进展:合成与应用
Chem Rev. 2023 Jan 17;123(4):1364-416. doi: 10.1021/acs.chemrev.2c00591.
2
Enantioselective synthesis of atropisomeric benzamides through peptide-catalyzed bromination.通过肽催化溴化反应对映选择性合成非对映异构体苯甲酰胺。
J Am Chem Soc. 2013 Feb 27;135(8):2963-6. doi: 10.1021/ja400082x. Epub 2013 Feb 14.
3
4-Chloro-7-hydr-oxy-6-methyl-1,7-naphthyridin-8(7H)-one.4-氯-7-羟基-6-甲基-1,7-萘啶-8(7H)-酮
Acta Crystallogr Sect E Struct Rep Online. 2009 Nov 28;65(Pt 12):o3259. doi: 10.1107/S1600536809050429.